Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments.
Using retrospectively collected outcome data for treatment naïve subjects treated with either glatiramer acetate (GA) (n=332) or interferon beta (IFN β) (n=424), we replicated the lack of a significant difference in efficacy between these treatments. Further, for both treatments, we observed a decline in the hazard of a relapse over time, which may suggest the existence of subsets of subjects with differential responses to each treatment. The HLA DRB1 1501 allele explained some of this variation in event-free survival while on GA, and we found suggestive evidence that an IRF8 polymorphism influences event-free survival in IFN β treated subjects.
Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Robert
R
Gross
Brian C
BC
Healy
Sabine
S
Cepok
Tanuja
T
Chitnis
Samia J
SJ
Khoury
Bernard
B
Hemmer
Howard L
HL
Weiner
David A
DA
Hafler
Philip L
PL
De Jager
D000328:Adult; D004351:Drug Resistance / Q000235:genetics / Q000276:immunology; D005260:Female; D000068717:Glatiramer Acetate; D006684:HLA-DR Antigens / Q000235:genetics*; D059811:HLA-DRB1 Chains; D006801:Humans; D050835:Interferon Regulatory Factors / Q000235:genetics; D016899:Interferon-beta / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D012189:Retrospective Studies; D000099185:Interferon Regulatory Factor-8
D000068717:Glatiramer Acetate; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D050835:Interferon Regulatory Factors; D016899:Interferon-beta; D010455:Peptides; D000099185:Interferon Regulatory Factor-8; C489631:HLA-DRB1*15:01 antigen